Results for tag: "Zilretta"

Zilretta is a brand of musculoskeletal disorder drugs developed by Flexion Therapeutics. It is a long-acting, injectable, non-opioid treatment for osteoarthritis pain. Zilretta is a triamcinolone acetonide extended-release formulation that is administered as a single intra-articular injection. It is designed to provide sustained pain relief over a period of up to 12 weeks. Zilretta is the first and only FDA-approved extended-release intra-articular treatment for osteoarthritis knee pain. The Zilretta market is a rapidly growing segment of the musculoskeletal disorder drugs market. It is driven by the increasing prevalence of osteoarthritis, the growing demand for non-opioid treatments, and the increasing availability of Zilretta. The market is expected to continue to grow in the coming years, as more patients seek out non-opioid treatments for their osteoarthritis pain. Some of the major companies in the Zilretta market include Flexion Therapeutics, Pfizer, Merck, and Novartis. These companies are actively involved in the development and marketing of Zilretta and other musculoskeletal disorder drugs. Show Less Read more